PWS Nanocytology Cancer Risk Stratification LDT

About NanoCytomics

NanoCytomics is a private, pre-revenue diagnostics company leveraging its proprietary PWS (Partial Wave Spectroscopy) Nanocytology platform to create non-invasive cancer risk stratification tests. Founded by a team of leading academics, the company aims to deploy simple sample collection in primary care settings, with results guiding the need for more invasive, gold-standard diagnostics. Its first Laboratory Developed Test (LDT) was anticipated for 2018, targeting significant improvements in early cancer detection and healthcare cost reduction.

Therapeutic Areas